Daijiro Harada

2.4k total citations
73 papers, 1.2k citations indexed

About

Daijiro Harada is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daijiro Harada has authored 73 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 47 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Daijiro Harada's work include Lung Cancer Treatments and Mutations (47 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (20 papers). Daijiro Harada is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (20 papers). Daijiro Harada collaborates with scholars based in Japan, United States and India. Daijiro Harada's co-authors include Katsuyuki Kiura, Nagio Takigawa, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Ochi, Toshio Kubo, Takashi Ninomiya, Toshiyuki Kozuki, Naoyuki Nogami and Yoshinobu Maeda and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Daijiro Harada

68 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daijiro Harada Japan 18 835 699 362 190 102 73 1.2k
Chundong Gu China 20 299 0.4× 357 0.5× 535 1.5× 238 1.3× 97 1.0× 51 1.0k
Iosune Baraibar Spain 17 572 0.7× 288 0.4× 319 0.9× 214 1.1× 208 2.0× 44 904
Shu Zhao China 21 785 0.9× 337 0.5× 490 1.4× 409 2.2× 134 1.3× 43 1.4k
Shazli N. Malik United States 13 411 0.5× 400 0.6× 801 2.2× 232 1.2× 147 1.4× 16 1.2k
Kamila Wojas‐Krawczyk Poland 15 384 0.5× 314 0.4× 220 0.6× 125 0.7× 53 0.5× 77 751
Alma D. Campos-Parra Mexico 23 420 0.5× 441 0.6× 761 2.1× 703 3.7× 69 0.7× 45 1.3k
Ute Sartorius Germany 11 567 0.7× 235 0.3× 300 0.8× 137 0.7× 212 2.1× 23 833
Li Yan China 18 336 0.4× 178 0.3× 393 1.1× 206 1.1× 63 0.6× 54 872

Countries citing papers authored by Daijiro Harada

Since Specialization
Citations

This map shows the geographic impact of Daijiro Harada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daijiro Harada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daijiro Harada more than expected).

Fields of papers citing papers by Daijiro Harada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daijiro Harada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daijiro Harada. The network helps show where Daijiro Harada may publish in the future.

Co-authorship network of co-authors of Daijiro Harada

This figure shows the co-authorship network connecting the top 25 collaborators of Daijiro Harada. A scholar is included among the top collaborators of Daijiro Harada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daijiro Harada. Daijiro Harada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tamiya, Akihiro, Daijiro Harada, Shun‐ichi Isa, et al.. (2024). Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer. Lung Cancer. 195. 107917–107917. 4 indexed citations
2.
Morita, Ayako, Eiki Ichihara, Koji Inoue, et al.. (2024). Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer. International Journal of Cancer. 154(9). 1607–1615. 14 indexed citations
3.
Nakamichi, Shinji, Kaoru Kubota, Toshihiro Misumi, et al.. (2024). Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study). Clinical Cancer Research. 30(6). 1104–1110. 8 indexed citations
4.
Kondo, Tetsuro, Kaoru Kubota, Shinji Nakamichi, et al.. (2023). 1294P A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study). Annals of Oncology. 34. S746–S747. 1 indexed citations
5.
Kubo, Toshio, Eiki Ichihara, Daijiro Harada, et al.. (2023). Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. Respiratory Investigation. 61(5). 643–650. 3 indexed citations
6.
Yamada, Manabu, Mitsuyo Kohara, Hideki Hirakawa, et al.. (2023). Plant GARDEN: a portal website for cross-searching between different types of genomic and genetic resources in a wide variety of plant species. BMC Plant Biology. 23(1). 391–391. 9 indexed citations
7.
Hosokawa, Shinobu, Eiki Ichihara, Daijiro Harada, et al.. (2022). Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801. International Journal of Clinical Oncology. 27(7). 1139–1144. 4 indexed citations
8.
Ochi, Nobuaki, Eiki Ichihara, Nagio Takigawa, et al.. (2021). The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. European Journal of Cancer. 149. 73–81. 43 indexed citations
9.
Hara, Naofumi, Eiki Ichihara, Daijiro Harada, et al.. (2021). Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology. 147(12). 3749–3755. 7 indexed citations
10.
Harada, Daijiro & Nagio Takigawa. (2021). Oligoprogression in Non-Small Cell Lung Cancer. Cancers. 13(22). 5823–5823. 15 indexed citations
11.
Miyake, Noriko, Nobuaki Ochi, Hiromichi Yamane, et al.. (2021). Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells. Experimental Cell Research. 409(2). 112940–112940. 4 indexed citations
12.
Ichihara, Eiki, Daijiro Harada, Koji Inoue, et al.. (2020). Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 70(1). 101–106. 28 indexed citations
13.
Kano, Hirohisa, Eiki Ichihara, Daijiro Harada, et al.. (2020). Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status. Cancer Science. 111(10). 3739–3746. 18 indexed citations
14.
Ichihara, Eiki, Daijiro Harada, Koji Inoue, et al.. (2019). The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer. 139. 140–145. 74 indexed citations
15.
Tsukita, Yoko, Akira Inoue, Shunichi Sugawara, et al.. (2019). Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203. Lung Cancer. 139. 89–93. 15 indexed citations
16.
Hotta, Katsuyuki, Keisuke Aoe, Toshiyuki Kozuki, et al.. (2017). A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(2). 273–279. 123 indexed citations
17.
Oda, Naohiro, Eiki Ichihara, Katsuyuki Hotta, et al.. (2016). Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clinical Lung Cancer. 18(2). 241–244. 8 indexed citations
18.
Ochi, Nobuaki, Nagio Takigawa, Daijiro Harada, et al.. (2014). Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Experimental Cell Research. 322(1). 168–177. 41 indexed citations
19.
Harada, Daijiro, Nagio Takigawa, Nobuaki Ochi, et al.. (2012). JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation. Cancer Science. 103(10). 1795–1802. 38 indexed citations
20.
Kubo, Toshio, Nagio Takigawa, Daijiro Harada, et al.. (2012). Subpopulation of small‐cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Science. 104(1). 78–84. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chundong Gu Breakdown of academic impact, for papers by Iosune Baraibar Breakdown of academic impact, for papers by Shu Zhao Breakdown of academic impact, for papers by Shazli N. Malik Breakdown of academic impact, for papers by Kamila Wojas‐Krawczyk Breakdown of academic impact, for papers by Alma D. Campos-Parra Breakdown of academic impact, for papers by Ute Sartorius Breakdown of academic impact, for papers by Li Yan
Rankless by CCL
2026